Hikma Pharmaceuticals (LON:HIK) Stock Price Down 14.1% – What’s Next?

Hikma Pharmaceuticals PLC (LON:HIK)’s share price was down 14.1% during mid-day trading on Thursday . The company traded as low as GBX 1,522 and last traded at GBX 1,522. Approximately 166,325,172 shares changed hands during mid-day trading, an increase of 7,989% from the average daily volume of 2,056,107 shares. The stock had previously closed at GBX 1,771.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on HIK shares. Berenberg Bank dropped their price target on shares of Hikma Pharmaceuticals from GBX 2,560 to GBX 2,510 and set a “buy” rating on the stock in a research note on Thursday, October 16th. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,600 price target on shares of Hikma Pharmaceuticals in a research note on Thursday, August 7th. JPMorgan Chase & Co. dropped their price target on shares of Hikma Pharmaceuticals from GBX 2,600 to GBX 2,500 and set an “overweight” rating on the stock in a research note on Friday, August 8th. Finally, Deutsche Bank Aktiengesellschaft dropped their price target on shares of Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a “buy” rating on the stock in a research note on Tuesday, August 12th. Four investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of GBX 2,615.

Hikma Pharmaceuticals Stock Down 14.1%

The company has a current ratio of 1.66, a quick ratio of 1.27 and a debt-to-equity ratio of 55.82. The firm has a market cap of £3.37 billion, a P/E ratio of 9.11, a PEG ratio of 2.38 and a beta of 0.41. The company’s 50 day simple moving average is GBX 1,734.94 and its 200-day simple moving average is GBX 1,896.07.

Insider Activity

In related news, insider Laura Balan Balan bought 3,500 shares of the stock in a transaction on Friday, August 22nd. The shares were acquired at an average price of GBX 1,821 per share, for a total transaction of £63,735. Also, insider Mazen Darwazah bought 14,000 shares of the stock in a transaction on Tuesday, September 16th. The shares were bought at an average price of GBX 1,603 per share, for a total transaction of £224,420. 17.77% of the stock is currently owned by corporate insiders.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.